MPH

The New York Academy of Medicine Awards 2024-2026 Jeremiah A. Barondess Fellowship in the Clinical Transaction

Retrieved on: 
Friday, March 8, 2024
Doctor of Philosophy, CNM, Accreditation Council, Graduate medical education, Education, Assistant, Physician, Accreditation, Social, Curriculum, Conference, Society, NYAM, Health, Patient, MPH, Internal medicine, Pediatrics, Health equity, MACP, ACGME, Fellow, Med-Peds, Hospital medicine, Nursing

Dr. Murphy’s educational intervention supported by the Fellowship focuses on teaching residents to integrate social determinants of health (SDoH) into clinical reasoning and developing patient-centered plans.

Key Points: 
  • Dr. Murphy’s educational intervention supported by the Fellowship focuses on teaching residents to integrate social determinants of health (SDoH) into clinical reasoning and developing patient-centered plans.
  • The Barondess Fellowship is awarded to junior faculty members in internal medicine to enhance medical students’ and residents’ training in the clinical transaction, a fundamental element of clinical care.
  • Dr. Murphy is an Assistant Professor of Medicine and Pediatrics at the Johns Hopkins University School of Medicine (JHUSOM).
  • She plans to use the Barondess Fellowship to develop a practical, patient-facing SDoH curriculum for the Osler Medical Residency Training Program at JHUSOM.

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, March 7, 2024
Conference call, Fluticasone, Sinusitis, Telephone, Inflammation, FDA, Food, Shanda, Conference, Ear, Safety, OPTN, ENT, Webcast, Patient, Journal, MPH, Medicine, Research, Nose, Pharmaceutical industry

YARDLEY, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational highlights.

Key Points: 
  • In addition, during 2023 we worked hard to prepare our organization to make the most of the new opportunity.
  • For the three-month and twelve-month periods ended December 31, 2023, research and development expenses were $1.3 million and $5.3 million, respectively.
  • The net loss for the three-month period ended December 31, 2023 was $10.0 million, or $0.09 per share (basic and diluted).
  • The net loss for the twelve-month period ended December 31, 2023 was $35.5 million, or $0.32 per share (basic and diluted).

Power of Amwell Hybrid Care Solutions to be Highlighted at HIMSS 2024

Retrieved on: 
Wednesday, March 6, 2024
BSN, RN, HIMSS, EST, MBA, Northwell Health, Associate, MPH, Automation, Obstetrics, Nursing

Boston, March 06, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in hybrid care enablement, is attending HIMSS 2024 , March 11-15, in Orlando, Fla. Company leaders will be in booth #1441 to discuss Amwell’s hybrid care enablement platform, Virtual Nursing solution, automated care and behavioral health programs and how this technology can address workforce shortages, access to care, the mental health crisis and other industry challenges.

Key Points: 
  • Boston, March 06, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leader in hybrid care enablement, is attending HIMSS 2024 , March 11-15, in Orlando, Fla. Company leaders will be in booth #1441 to discuss Amwell’s hybrid care enablement platform, Virtual Nursing solution, automated care and behavioral health programs and how this technology can address workforce shortages, access to care, the mental health crisis and other industry challenges.
  • Northern Light Health uses the Amwell ConvergeTM platform, integrated with its electronic health record, as well as Amwell hardware devices, to support a variety of programs designed to improve patient and provider experiences.
  • El Camino Health and Northwell Health use Amwell Automated Care Programs to provide chat-based virtual companions for post-discharge, pre- and post-surgery, chronic conditions, obstetrics and more.
  • For more information about Amwell at HIMSS, or to talk with a company leader during the event, contact [email protected] .

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Retrieved on: 
Tuesday, March 5, 2024
Paragon, Well, SAD, PD, Injection, I&I, Waldman, Headache, Inflammation, Quality of life, Management, Atopic dermatitis, Asthma, TARC, AUC, Volunteering, Cmax, Chronic obstructive pulmonary disease, Outline of health sciences, Safety, Biomarker, Therapy, CQD, Chronic pain, Immunology, IGA, Webcast, Sleep, Patient, MPH, Half-life, Serum, Pharmaceutical industry

Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.

Key Points: 
  • Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
  • At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.
  • The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and PK of APG777 in healthy volunteers.
  • A live webcast of the call will be available on the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Friday, March 1, 2024
CGEM, Escape Room, FDA, Food, SITC, MBA, MICA, Bone marrow, Immunoglobulin G, MICB, Malignancy, Patient, MPH, Multiple myeloma, IND, Trial of the century, Vaccine

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN-619 in relapsed/refractory multiple myeloma. CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to stress-induced ligands, MICA and MICB, which are expressed on a wide variety of solid tumors and hematologic malignancies. The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.

Key Points: 
  • The company will commence a Phase 1 dose-escalation and dose-expansion trial of CLN-619.
  • “Multiple myeloma remains incurable, and most patients experience sequential relapses.
  • The response to treatment is typically shorter with each relapse, so novel treatments are still needed,” said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Oncology.
  • “Multiple myeloma is another example of a malignancy where MICA/B shedding from tumor cells allows for immune evasion.

American Urological Association Releases Salvage Therapy for Prostate Cancer Guideline

Retrieved on: 
Thursday, February 29, 2024
Therapy, Recurrence, Salvage therapy, Prostate cancer, Professor, ASTRO, Quality of life, Metastasis, Patient, Radiation, Risk, Society, University, AUA, SUO, Guideline, MPH, American Urological Association, Radiation therapy, Panel, Partnership, Medical imaging

BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.

Key Points: 
  • BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.
  • Understanding the evaluation and appropriate use of salvage therapies for patients with biochemical recurrence is a critical area of prostate cancer care.
  • “Thanks to the incredible expertise of the entire Panel, this guideline helps provide a roadmap that combines the latest advancements with thoughtful recommendations, empowering patients and clinicians alike.”
    This guideline has 30 recommendations and is a useful reference for effective evidence-based care related to salvage therapy for prostate cancer.
  • Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy.

One in Two Employees Rank Physical Activity and Weight Loss as Top Strategies for Heart Health

Retrieved on: 
Wednesday, February 28, 2024
MPH, PHD, Obesity, Health, Weight loss, Anxiety, Sleep, Movement, Doctor of Philosophy, Dietary supplement

Dallas, TX, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Physical activity and weight loss top the list of ways employees improve their heart health, according to new survey results from Wondr Health.

Key Points: 
  • Dallas, TX, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Physical activity and weight loss top the list of ways employees improve their heart health, according to new survey results from Wondr Health.
  • The proven leader in metabolic, emotional, and physical health transformation, Wondr Health conducted the survey in February 2024.
  • When asked how they prioritize heart health, nearly 700 respondents indicated physical activity, stress management, and weight loss as the top three strategies:
    “The benefits of physical activity have been well documented when it comes to heart health in addition to overall mental and physical health,” said Tim Church, MD, MPH, PHD, Chief Medical Officer, Wondr Health.
  • “Physical activity even plays an important role in weight-loss medication use.”
    A recent report from leading obesity experts found that in addition to the heart health benefits, physical activity may reduce the loss of lean muscle from weight-loss medications and improve the quality and function of muscles.

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

Retrieved on: 
Tuesday, February 27, 2024
BRAF, Therapy, SAN, Eventide, Research, AML, GSK, PARP, Cancer, Platinum, Portfolio manager, Drug development, Uterine serous carcinoma, Medication, Webcast, Ovarian cancer, Administration, PROC, USC, Patient, Pharming, MPH, Link, Development, NDA, WEE1, Acute myeloid leukemia, Partnership, Pharmaceutical industry

NEW YORK and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the year ended December 31, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • "Zentalis is making remarkable progress in advancing our clinical development program for azenosertib, our potentially groundbreaking WEE1 inhibitor, across various tumor types," stated Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis.
  • "In November 2023, we disclosed promising clinical data demonstrating the potential of azenosertib as an effective monotherapy in ovarian cancer and uterine serous carcinoma.
  • On November 10, 2023, Zentalis participated in a webcast with Joyce F. Liu, M.D., MPH, to discuss azenosertib ovarian cancer clinical data.
  • General and Administrative Expenses: General and administrative expenses for the year ended December 31, 2023 were $64.4 million, compared to $54.6 million during the year ended December 31, 2022.

Arcadia Launches Data Platform to Unlock Speed, Reliability, and Scale for Healthcare Enterprises

Retrieved on: 
Tuesday, February 27, 2024
ETL, Acquisition, Architecture, Artificial intelligence, AI, Health, Transport, FHIR, Data management, Technical, Telemetry, EHR, Growth, Data science, Conference, API, Ides, Ecosystem, MPH, Sureserve

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arcadia ( arcadia.io ), a healthcare technology company that provides a leading data platform to providers and payers, unveiled today its next-generation data platform powered by an open lakehouse architecture to enhance healthcare organizations’ abilities to harness big data.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arcadia ( arcadia.io ), a healthcare technology company that provides a leading data platform to providers and payers, unveiled today its next-generation data platform powered by an open lakehouse architecture to enhance healthcare organizations’ abilities to harness big data.
  • Arcadia’s next-generation data platform is generally available and has been deployed to more than 15 customers, including Umpqua Health.
  • "At Umpqua Health, data is the cornerstone of our operational strategy," said Juliana Landry, MPH, Vice President of Health Systems Performance.
  • "Our focus on enhancing performance ensures the rapid delivery of updated data to our care teams, significantly improving our processes.

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Retrieved on: 
Monday, February 26, 2024
Sildenafil, Therapy, Pfizer, RSU, Marketing, Common stock, Public health, IRON, Ascending cholangitis, Lumacaftor/ivacaftor, Ipsen, Brown University, Vertex Pharmaceuticals, Patient, Pregabalin, Public, MPH, Policy, Pharmaceutical industry

WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.

Key Points: 
  • WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.
  • “We are delighted to welcome an accomplished leader such as Pamela to Disc, where her breadth of commercial experience and acumen will be instrumental as the company continues to grow,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
  • Most recently, she served as the Chief Commercial Officer of Albireo, which was acquired by Ipsen, spearheading the successful launch of Bylvay for a rare cholestatic liver disease.
  • The Inducement Award was approved by Disc’s Board of Directors (the “Board”), including a majority of the independent directors serving on the Board.